within Pharmacolibrary.Drugs.ATC.J;

model J01XX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 8.499999999999999e-05,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00078,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007500000000000001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XX07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nitroxoline is a quinoline derivative antibiotic formerly widely used for urinary tract infections (UTIs), particularly in Europe. It acts primarily through inhibition of bacterial DNA synthesis. Although its use has declined in some regions, nitroxoline remains approved and clinically available in others for treatment of uncomplicated lower UTIs.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Wijma, RA, et al., &amp; Muller, AE (2018). Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. <i>The Journal of antimicrobial chemotherapy</i> 73(11) 2916–2926. DOI:<a href=\"https://doi.org/10.1093/jac/dky255\">10.1093/jac/dky255</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30184207/\">https://pubmed.ncbi.nlm.nih.gov/30184207</a></p></li><li><p>Bergogne-Berezin, E, et al., &amp; Muller-Serieys, C (1987). [Present status of nitroxoline]. <i>Pathologie-biologie</i> 35(5 Pt 2) 873–878. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3309832/\">https://pubmed.ncbi.nlm.nih.gov/3309832</a></p></li><li><p>Wagenlehner, FM, et al., &amp; Naber, KG (2014). Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers. <i>Antimicrobial agents and chemotherapy</i> 58(2) 713–721. DOI:<a href=\"https://doi.org/10.1128/AAC.02147-13\">10.1128/AAC.02147-13</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24217699/\">https://pubmed.ncbi.nlm.nih.gov/24217699</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XX07;
